1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
2Heijtink RA, Janssen HL, Hop WC, et al. Interferon-alpha therapy in chronic hepatitis B:early monitoring of HBeAg may help to decide whether to stop or prolong therapy[J]. Jvira; Hepat,2000,7:382-386.
3Fried M,Liam Y-F,Luo k . Role of baseline and on-treatment quantitative HBeAg levels in prediciting response to peginterferon a; da-2a (40KD) (pegasys)montherapy in a large, multinational trial of patients with chronic hepatitis B Hepatology[J]. 2005,42:268A.
4Park NH,shin JW,park JH,et al . monitoring of HBeAg levels may help to predict the outcomes of Lamivudipe therapy for HBeA gpositive chronic hepatitis B J viral hepat[J ] . 2005,12:216-221 .
5Hou JL,Yin Yk,Xu DZ,et al . A phase Ⅲ comparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in chinese patients:first year resuh.prensented at:shanghai-hongkong international liver congress: 2006.
6Bzowej N,Chan LYH,Lai CL,et al. A randomized trial of telbivudine (LDT)vs.adefovir for HBeAg-positive chronic hepatitis B: final week 52 resuts[J]. Hepatolog,2006,44(4 suppl 1 ) :563A.
